Skin Therapy Letter HOME
Written for dermatologists by dermatologists. Indexed by the US National Library of Medicine.
Skin Information
NETWORK
Skin Therapy Letter About STL Subscribe Today SkinCareGuide Network Site Map
CUSTOM DERMATOLOGY SEARCH:
Loading

Update on Drugs - May 2009


Name/Company Approval Dates and Comments

Alitretinion
Toctino®
Basilea Pharmaceutica

The health authorities in Austria, Belgium, and Luxembourg approved this new once-daily oral treatment in March 2009 for the treatment of adults with severe chronic hand eczema unresponsive to potent topical corticosteroids.

Pralatrexate
Allos Therapeutics

The US FDA received a New Drug Application in March 2009 for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Benzyl Alcohol Lotion 5%
Sciele Pharma

The US FDA approved this new prescription non-neurotoxic medication in April 2009 for the treatment of head lice in patients 6 months of age and older. This product kills head lice by asphyxiation without potential neurotoxic side-. effects.

Botulinum Toxin – Type A
Azzalure®
Galderma/Ipsen

The Danish Medicines Agency (DKMA) approved this once-daily oral treatment in September 2008 for the treatment of adults with severe chronic hand eczema that is unresponsive to potent topical corticosteroids. Marketing applications for this product are also under review in Canada and Switzerland.

Drug News

The Genentech unit of Roche Holding AG reported in April 2009, that it is pulling the psoriasis treatment Efalizumab (Raptiva®) off the US market because of links to an often fatal brain infection. The drug was approved by the US FDA for patients with chronic moderate-to-severe plaque psoriasis and this move comes only about 6 months after the drug’s labeling was updated to carry warnings of links to progressive multifocal leukoencephalopathy. The company said no new prescriptions should be written, and the drug will no longer be available at all after June 8, 2009. Genentech says patients should talk with their doctors before stopping treatment with the drug, because abruptly halting it can lead to sudden worsening of their psoriasis.

Health Canada and Allergan are informing healthcare professionals about important safety information related to botulinum toxin – type A and the potential risk of serious adverse effects of muscle weakness remote to the injection site. Key safety updates within the new product monographs for this neurotoxin include:

  • Patients may experience muscle weakness remote to the injection site. Possible symptoms include muscle weakness, dysphagia, aspiration pneumonia, speech disorders, and respiratory depression. These reactions can be fatal.
  • Patients or caregivers should be advised to seek immediate medical care if swalling, speech or respiratory disorders arise.
  • Botulinum toxin – type A should only be given by physicians with appropriate qualifications and experience in the use of this product. The revised product monographs emphasize the need to follow the recommended dosage and frequency of administration.
  • Patients with a history of underlying neurological disorders, dysphagia and/or aspiration should be treated with extreme caution.

Any case of serious suspected distant toxin spread or other serious or unexpected adverse reactions in patients receiving botulinum toxin – type A should be reported to Allergan or Health Canada.


In this issue:

  1. Treatments for Scalp Psoriasis with Emphasis on Calcipotriol Plus Betamethasone Dipropionate Gel (Xamiol®)
  2. Use of Tacrolimus Ointment in Vitiligo Alone or in Combination Therapy
  3. Update on Drugs and Drug News - May 2009